Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact the trial administrator to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, 90502
- UCLA CARE Center CRS (601), Los Angeles, California, 90095
- Ucsd, Avrc Crs (701), San Diego, California, 92103
- Stanford CRS (501), Palo Alto, California, 94304
- Ucsf Aids Crs (801), San Francisco, California, 94110
-
Colorado
- University of Colorado Hospital CRS (6101), Aurora, Colorado, 80045
-
Texas
- Houston AIDS Research Team CRS (31473), Houston, Texas, 77030
-
Missouri
- Washington U CRS (2101), St. Louis, Missouri, 63110
-
Illinois
- Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago, Illinois, 60612
- Northwestern University CRS (2701), Chicago, Illinois, 60611
-
Tennessee
- Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, 37232
-
Alabama
- Alabama Therapeutics CRS (5801), Birmingham, Alabama, 35294
-
Ohio
- Univ. of Cincinnati CRS (2401), Cincinnati, Ohio, 45267
Powered by
SC CTSI